Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Benjamin P. Sablan, Dong Joon Kim, Nina G. Barzaga, Wan Cheng Chow, Mong Cho, Sang Hoon Ahn, Seong Gyu Hwang, Ji Hyun Lee, Hamid Namini, William L. Heyward

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

Original languageEnglish
Pages (from-to)2689-2696
Number of pages8
JournalVaccine
Volume30
Issue number16
DOIs
Publication statusPublished - 2012 Mar 30

Fingerprint

Hepatitis B Vaccines
hepatitis B
Hepatitis B Surface Antigens
Hepatitis B
Vaccines
vaccines
Safety
Hepatitis B virus
Toll-Like Receptor 9
dosage
agonists
adjuvants
Population
hepatitis B antigens

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Sablan, Benjamin P. ; Kim, Dong Joon ; Barzaga, Nina G. ; Chow, Wan Cheng ; Cho, Mong ; Ahn, Sang Hoon ; Hwang, Seong Gyu ; Lee, Ji Hyun ; Namini, Hamid ; Heyward, William L. / Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. In: Vaccine. 2012 ; Vol. 30, No. 16. pp. 2689-2696.
@article{7753d5af86844e45a02dea95ed8f2f20,
title = "Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine",
abstract = "Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B{\circledR}). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.",
author = "Sablan, {Benjamin P.} and Kim, {Dong Joon} and Barzaga, {Nina G.} and Chow, {Wan Cheng} and Mong Cho and Ahn, {Sang Hoon} and Hwang, {Seong Gyu} and Lee, {Ji Hyun} and Hamid Namini and Heyward, {William L.}",
year = "2012",
month = "3",
day = "30",
doi = "10.1016/j.vaccine.2012.02.001",
language = "English",
volume = "30",
pages = "2689--2696",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "16",

}

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. / Sablan, Benjamin P.; Kim, Dong Joon; Barzaga, Nina G.; Chow, Wan Cheng; Cho, Mong; Ahn, Sang Hoon; Hwang, Seong Gyu; Lee, Ji Hyun; Namini, Hamid; Heyward, William L.

In: Vaccine, Vol. 30, No. 16, 30.03.2012, p. 2689-2696.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

AU - Sablan, Benjamin P.

AU - Kim, Dong Joon

AU - Barzaga, Nina G.

AU - Chow, Wan Cheng

AU - Cho, Mong

AU - Ahn, Sang Hoon

AU - Hwang, Seong Gyu

AU - Lee, Ji Hyun

AU - Namini, Hamid

AU - Heyward, William L.

PY - 2012/3/30

Y1 - 2012/3/30

N2 - Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

AB - Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

UR - http://www.scopus.com/inward/record.url?scp=84862785552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862785552&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.02.001

DO - 10.1016/j.vaccine.2012.02.001

M3 - Article

C2 - 22342916

AN - SCOPUS:84862785552

VL - 30

SP - 2689

EP - 2696

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 16

ER -